Nitric oxide synthase in post-ischaemic remodelling: New pathways and mechanisms

Cardiovascular Research

Volumn 94, Issue 2, 2012, Pages 304-315

  Manoury, Boris ^a,b   Montiel, Virginie ^a   Balligand, Jean Luc ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Cardiac remodelling; Heart failure; Hypertrophy; Nitric oxide synthase; Protein kinase G

Indexed keywords

BETA 3 ADRENERGIC RECEPTOR; CINACIGUAT; CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FOLIC ACID; GUANYLATE CYCLASE ACTIVATOR; INDUCIBLE NITRIC OXIDE SYNTHASE; NEURONAL NITRIC OXIDE SYNTHASE; PHOSPHODIESTERASE 5A INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; TETRAHYDROBIOPTERIN; UNCLASSIFIED DRUG;

ADRENERGIC SYSTEM; HEART; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART VENTRICLE REMODELING; HUMAN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ANIMALS; HEART FAILURE; HUMANS; MICE; MYOCARDIUM; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; SIGNAL TRANSDUCTION; VENTRICULAR REMODELING;

EID: 84860137298     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvr360     Document Type: Review

References (114)

1. Balligand JL, Feron O, Dessy C. eNOS activation by physical forces: from short-term regulation of contraction to chronic remodeling of cardiovascular tissues. Physiol Rev 2009;89:481-534.
2. Lim G, Venetucci L, Eisner DA, Casadei B. Does nitric oxide modulate cardiac ryanodine receptor function? Implications for excitation-contraction coupling. Cardiovasc Res 2008;77:256-264. (Pubitemid 351197636)
3. Dedkova EN, Blatter LA. Characteristics and function of cardiac mitochondrial nitric oxide synthase. J Physiol 2009;587:851-872.
4. Bendall JK, Damy T, Ratajczak P, Loyer X, Monceau V, Marty I et al. Role of myocardial neuronal nitric oxide synthase-derived nitric oxide in b-adrenergic hyporesponsiveness after myocardial infarction-induced heart failure in rat. Circulation 2004;110: 2368-2375. (Pubitemid 39407341)
5. Belge C, Massion PB, Pelat M, Balligand JL. Nitric oxide and the heart: update on new paradigms. Ann N Y Acad Sci 2005;1047:173-182. (Pubitemid 41123838)
6. Hare JM, Stamler JS. NO/redox disequilibrium in the failing heart and cardiovascular system. J Clin Invest 2005;115:509-517. (Pubitemid 40322220)
7. Massion PB, Balligand JL. Relevance of nitric oxide for myocardial remodeling. Curr Heart Fail Rep 2007;4:18-25. (Pubitemid 46663315)
8. Hammond J, Balligand JL. Nitric oxide synthase and cyclic GMP signaling in cardiac myocytes: from contractility to remodeling. J Mol Cell Cardiol 2012;52:330-340.
9. Knoll R, Iaccarino G, Tarone G, Hilfiker-Kleiner D, Bauersachs J, Leite-Moreira AF et al. Towards a re-definition of 'cardiac hypertrophy' through a rational characterization of left ventricular phenotypes: a position paper of the Working Group 'Myocardial Function' of the ESC. Eur J Heart Fail 2011;13:811-819.
10. Ashley EA, Sears CE, Bryant SM, Watkins HC, Casadei B. Cardiac nitric oxide synthase 1 regulates basal and b-adrenergic contractility in murine ventricular myocytes. Circulation 2002;105:3011-3016. (Pubitemid 34693835)
11. Zhang YH, Zhang MH, Sears CE, Emanuel K, Redwood C, El-Armouche A et al. Reduced phospholamban phosphorylation is associated with impaired relaxation in left ventricular myocytes from neuronal NO synthase-deficient mice. Circ Res 2008;102:242-249. (Pubitemid 351651129)
12. Wang H, Viatchenko-Karpinski S, Sun J, Gyorke I, Benkusky NA, Kohr MJ et al. Regulation of myocyte contraction via neuronal nitric oxide synthase: role of ryanodine receptor S-nitrosylation. J Physiol 2010;588:2905-2917.
13. Barouch LA, Harrison RW, Skaf MW, Rosas GO, Cappola TP, Kobeissi ZA et al. Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms. Nature 2002;416:337-339.
14. Khan SA, Skaf MW, Harrison RW, Lee K, Minhas KM, Kumar A et al. Nitric oxide regulation of myocardial contractility and calcium cycling: independent impact of neuronal and endothelial nitric oxide synthases. Circ Res 2003;92:1322-1329. (Pubitemid 36773474)
15. Burkard N, Rokita AG, Kaufmann SG, Hallhuber M, Wu R, Hu K et al. Conditional neuronal nitric oxide synthase overexpression impairs myocardial contractility. Circ Res 2007;100:e32-e44.
16. Loyer X, Gomez AM, Milliez P, Fernandez-Velasco M, Vangheluwe P, Vinet L et al. Cardiomyocyte overexpression of neuronal nitric oxide synthase delays transition toward heart failure in response to pressure overload by preserving calcium cycling. Circulation 2008;117:3187-3198.
17. Mohamed TM, Oceandy D, Prehar S, Alatwi N, Hegab Z, Baudoin FM et al. Specific role of neuronal nitric-oxide synthase when tethered to the plasma membrane calcium pump in regulating the b-adrenergic signal in the myocardium. J Biol Chem 2009;284:12091-12098.
18. Damy T, Ratajczak P, Shah AM, Camors E, Marty I, Hasenfuss G et al. Increased neuronal nitric oxide synthase-derived NO production in the failing human heart. Lancet 2004;363:1365-1367. (Pubitemid 38529877)
19. Dawson D, Lygate CA, Zhang MH, Hulbert K, Neubauer S, Casadei B. nNOS gene deletion exacerbates pathological left ventricular remodeling and functional deterioration after myocardial infarction. Circulation 2005;112:3729-3737. (Pubitemid 43739513)
20. Saraiva RM, Minhas KM, Raju SV, Barouch LA, Pitz E, Schuleri KH et al. Deficiency of neuronal nitric oxide synthase increases mortality and cardiac remodeling after myocardial infarction: role of nitroso-redox equilibrium. Circulation 2005;112: 3415-3422. (Pubitemid 43739556)
21. Burkard N, Williams T, Czolbe M, Blomer N, Panther F, Link M et al. Conditional overexpression of neuronal nitric oxide synthase is cardioprotective in ischemia/reperfusion. Circulation 2010;122:1588-1603.
22. Mungrue IN, Gros R, You X, Pirani A, Azad A, Csont T et al. Cardiomyocyte overexpression of iNOS in mice results in peroxynitrite generation, heart block, and sudden death. J Clin Invest 2002;109:735-743. (Pubitemid 34263150)
23. Heger J, Godecke A, Flogel U, Merx MW, Molojavyi A, Kuhn-Velten WN et al. Cardiac-specific overexpression of inducible nitric oxide synthase does not result in severe cardiac dysfunction. Circ Res 2002;90:93-99. (Pubitemid 34074614)
24. Wunderlich C, Flogel U, Godecke A, Heger J, Schrader J. Acute inhibition of myoglobin impairs contractility and energy state of iNOS-overexpressing hearts. Circ Res 2003;92:1352-1358. (Pubitemid 36773478)
25. Feng Q, Lu X, Jones DL, Shen J, Arnold JM. Increased inducible nitric oxide synthase expression contributes to myocardial dysfunction and higher mortality after myocardial infarction in mice. Circulation 2001;104:700-704. (Pubitemid 32738526)
26. Wildhirt SM, Suzuki H, Horstman D, Weismuller S, Dudek RR, Akiyama K et al. Selective modulation of inducible nitric oxide synthase isozyme in myocardial infarction. Circulation 1997;96:1616-1623. (Pubitemid 27375361)
27. Sam F, Sawyer DB, Xie Z, Chang DL, Ngoy S, Brenner DA et al. Mice lacking inducible nitric oxide synthase have improved left ventricular contractile function and reduced apoptotic cell death late after myocardial infarction. Circ Res 2001;89: 351-356. (Pubitemid 34132674)
28. Saito T, Hu F, Tayara L, Fahas L, Shennib H, Giaid A. Inhibition of NOS II prevents cardiac dysfunction in myocardial infarction and congestive heart failure. Am J Physiol Heart Circ Physiol 2002;283:H339-H345. (Pubitemid 34705356)
29. Jones SP, Greer JJ,Ware PD, Yang J,Walsh K, Lefer DJ. Deficiency of iNOS does not attenuate severe congestive heart failure in mice. Am J Physiol Heart Circ Physiol 2005; 288:H365-H370. (Pubitemid 40023868)
30. Hataishi R, Rodrigues AC, Morgan JG, Ichinose F, Derumeaux G, Bloch KD et al. Nitric oxide synthase 2 and pressure-overload-induced left ventricular remodelling in mice. Exp Physiol 2006;91:633-639.
31. Dias FA, Urboniene D, Yuzhakova MA, Biesiadecki BJ, Pena JR, Goldspink PH et al. Ablation of iNOS delays cardiac contractile dysfunction in chronic hypertension. Front Biosci (Elite Ed) 2010;2:312-324.
32. Gealekman O, Abassi Z, Rubinstein I, Winaver J, Binah O. Role of myocardial inducible nitric oxide synthase in contractile dysfunction and b-adrenergic hyporesponsiveness in rats with experimental volume-overload heart failure. Circulation 2002; 105:236-243. (Pubitemid 34084325)
33. Funakoshi H, Kubota T, Machida Y, Kawamura N, Feldman AM, Tsutsui H et al. Involvement of inducible nitric oxide synthase in cardiac dysfunction with tumor necrosis factor-a. Am J Physiol Heart Circ Physiol 2002;282:H2159-H2166. (Pubitemid 34663026)
34. Ziolo MT, Maier LS, Piacentino V III, Bossuyt J, Houser SR, Bers DM. Myocyte nitric oxide synthase 2 contributes to blunted b-adrenergic response in failing human hearts by decreasing Ca2+ transients. Circulation 2004;109:1886-1891. (Pubitemid 38509124)
35. Balligand JL, Ungureanu-Longrois D, Simmons WW, Pimental D, Malinski TA, Kapturczak M et al. Cytokine-inducible nitric oxide synthase (iNOS) expression in cardiac myocytes. Characterization and regulation of iNOS expression and detection of iNOS activity in single cardiac myocytes in vitro. J Biol Chem 1994;269: 27580-27588.
36. Somers JR, Beck PL, Lees-Miller JP, Roach D, Li Y, Guo J et al. iNOS in cardiac myocytes plays a critical role in death in a murine model of hypertrophy induced by calcineurin. Am J Physiol Heart Circ Physiol 2008;295:H1122-H1131.
37. Jones SP, Bolli R. The ubiquitous role of nitric oxide in cardioprotection. J Mol Cell Cardiol 2006;40:16-23. (Pubitemid 43012113)
38. Patel HH, Hsu AK, Gross GJ. COX-2 and iNOS in opioid-induced delayed cardioprotection in the intact rat. Life Sci 2004;75:129-140. (Pubitemid 38553870)
39. West MB, Rokosh G, Obal D, Velayutham M, Xuan YT, Hill BG et al. Cardiac myocyte-specific expression of inducible nitric oxide synthase protects against ischemia/reperfusion injury by preventing mitochondrial permeability transition. Circulation 2008;118:1970-1978.
40. Massion PB, Dessy C, Desjardins F, Pelat M, Havaux X, Belge C et al. Cardiomyocyte-restricted overexpression of endothelial nitric oxide synthase (NOS3) attenuates b-adrenergic stimulation and reinforces vagal inhibition of cardiac contraction. Circulation 2004;110:2666-2672. (Pubitemid 39453017)
41. Petroff MG, Kim SH, Pepe S, Dessy C, Marban E, Balligand JL et al. Endogenous nitric oxide mechanisms mediate the stretch dependence of Ca2+ release in cardiomyocytes. Nat Cell Biol 2001;3:867-873. (Pubitemid 32952250)
42. Cappola TP, Cope L, Cernetich A, Barouch LA, Minhas K, Irizarry RA et al. Deficiency of different nitric oxide synthase isoforms activates divergent transcriptional programs in cardiac hypertrophy. Physiol Genomics 2003;14:25-34. (Pubitemid 37345212)
43. Ichinose F, Bloch KD, Wu JC, Hataishi R, Aretz HT, Picard MH et al. Pressure overload-induced LV hypertrophy and dysfunction in mice are exacerbated by congenital NOS3 deficiency. Am J Physiol Heart Circ Physiol 2004;286:H1070-H1075. (Pubitemid 38248623)
44. Ruetten H, Dimmeler S, Gehring D, Ihling C, Zeiher AM. Concentric left ventricular remodeling in endothelial nitric oxide synthase knockout mice by chronic pressure overload. Cardiovasc Res 2005;66:444-453. (Pubitemid 40725756)
45. Scherrer-Crosbie M, Ullrich R, Bloch KD, Nakajima H, Nasseri B, Aretz HT et al. Endothelial nitric oxide synthase limits left ventricular remodeling after myocardial infarction in mice. Circulation 2001;104:1286-1291. (Pubitemid 32848119)
46. Jones SP, Greer JJ, van Haperen R, Duncker DJ, de Crom R, Lefer DJ. Endothelial nitric oxide synthase overexpression attenuates congestive heart failure in mice. Proc Natl Acad Sci USA 2003;100:4891-4896. (Pubitemid 36457824)
47. Buys ES, Raher MJ, Blake SL, Neilan TG, Graveline AR, Passeri JJ et al. Cardiomyocyte-restricted restoration of nitric oxide synthase 3 attenuates left ventricular remodeling after chronic pressure overload. Am J Physiol Heart Circ Physiol 2007;293:H620-H627. (Pubitemid 47105123)
48. Janssens S, Pokreisz P, Schoonjans L, Pellens M, Vermeersch P, Tjwa M et al. Cardiomyocyte-specific overexpression of nitric oxide synthase 3 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circ Res 2004;94:1256-1262. (Pubitemid 38656413)
49. Sartoretto JL, Kalwa H, Pluth MD, Lippard SJ, Michel T. Hydrogen peroxide differentially modulates cardiac myocyte nitric oxide synthesis. Proc Natl Acad Sci USA 2011; 108:15792-15797.
50. Moens AL, Takimoto E, Tocchetti CG, Chakir K, Bedja D, Cormaci G et al. Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: efficacy of recoupling nitric oxide synthase as a therapeutic strategy. Circulation 2008; 117:2626-2636.
51. Okazaki T, Otani H, Shimazu T, Yoshioka K, Fujita M, Katano T et al. Reversal of inducible nitric oxide synthase uncoupling unmasks tolerance to ischemia/reperfusion injury in the diabetic rat heart. J Mol Cell Cardiol 2011;50:534-544.
52. Knoll R, Iaccarino G, Tarone G, Hilfiker-Kleiner D, Bauersachs J, Leite-Moreira AF et al. Towards a re-definition of 'cardiac hypertrophy' through a rational characterization of left ventricular phenotypes: a position paper of the Working Group 'Myocardial Function' of the ESC. Eur J Heart Fail 2011;13:811-819.
53. Calderone A, Thaik CM, Takahashi N, Chang DL, Colucci WS. Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest 1998;101:812-818. (Pubitemid 28096078)
54. Wollert KC, Fiedler B, Gambaryan S, Smolenski A, Heineke J, Butt E et al. Gene transfer of cGMP-dependent protein kinase I enhances the antihypertrophic effects of nitric oxide in cardiomyocytes. Hypertension 2002;39:87-92. (Pubitemid 34098094)
55. Takimoto E, Champion HC, Belardi D, Moslehi J, Mongillo M, Mergia E et al. cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism. Circ Res 2005;96:100-109. (Pubitemid 40095759)
56. Engelhardt S, Hein L, Dyachenkow V, Kranias EG, Isenberg G, Lohse MJ. Altered calcium handling is critically involved in the cardiotoxic effects of chronic b-adrenergic stimulation. Circulation 2004;109:1154-1160. (Pubitemid 38332620)
57. Houser SR. Ca2+ signaling domains responsible for cardiac hypertrophy and arrhythmias. Circ Res 2009;104:413-415.
58. Koitabashi N, Aiba T, Hesketh GG, Rowell J, Zhang M, Takimoto E et al. Cyclic GMP/PKG-dependent inhibition of TRPC6 channel activity and expression negatively regulates cardiomyocyte NFAT activation: novel mechanism of cardiac stress modulation by PDE5 inhibition. J Mol Cell Cardiol 2010;48:713-724.
59. Nakayama H, Bodi I, Correll RN, Chen X, Lorenz J, Houser SR et al. a1G-dependent T-type Ca2+ current antagonizes cardiac hypertrophy through a NOS3-dependent mechanism in mice. J Clin Invest 2009;119:3787-3796.
60. Lukowski R, Rybalkin SD, Loga F, Leiss V, Beavo JA, Hofmann F. Cardiac hypertrophy is not amplified by deletion of cGMP-dependent protein kinase I in cardiomyocytes. Proc Natl Acad Sci USA 2010;107:5646-5651.
61. Blanton RM, Takimoto E, Aronovitz M, Lane AM, Karas R, Mendelsohn ME et al. cGMP-dependent protein kinase I alpha is required for suppression of cardiac remodeling and controls early JNK activation in the heart after pressure overload. Circulation 2010;122:A20875.
62. Lee DI, Vahebi S, Tocchetti CG, Barouch LA, Solaro RJ, Takimoto E et al. PDE5A suppression of acute b-adrenergic activation requires modulation of myocyte beta-3 signaling coupled to PKG-mediated troponin I phosphorylation. Basic Res Cardiol 2010;105:337-347.
63. Lima B, Forrester MT, Hess DT, Stamler JS. S-nitrosylation in cardiovascular signaling. Circ Res 2010;106:633-646.
64. Gonzalez DR, Treuer AV, Castellanos J, Dulce RA, Hare JM. Impaired S-nitrosylation of the ryanodine receptor caused by xanthine oxidase activity contributes to calcium leak in heart failure. J Biol Chem 2010;285:28938-28945.
65. Khan SA, Lee K, Minhas KM, Gonzalez DR, Raju SV, Tejani AD et al. Neuronal nitric oxide synthase negatively regulates xanthine oxidoreductase inhibition of cardiac excitation-contraction coupling. Proc Natl Acad Sci USA 2004;101:15944-15948. (Pubitemid 39507906)
66. Benhar M, Forrester MT, Stamler JS. Protein denitrosylation: enzymatic mechanisms and cellular functions. Nat Rev Mol Cell Biol 2009;10:721-732.
67. Lima B, Lam GK, Xie L, Diesen DL, Villamizar N, Nienaber J et al. Endogenous S-nitrosothiols protect against myocardial injury. Proc Natl Acad Sci USA 2009;106: 6297-6302.
68. Kohr MJ, Sun J, Aponte A, Wang G, Gucek M, Murphy E et al. Simultaneous measurement of protein oxidation and S-nitrosylation during preconditioning and ischemia/reperfusion injury with resin-assisted capture. Circ Res 2011;108:418-426.
69. Burger DE, Lu X, Lei M, Xiang FL, Hammoud L, Jiang M et al. Neuronal nitric oxide synthase protects against myocardial infarction-induced ventricular arrhythmia and mortality in mice. Circulation 2009;120:1345-1354.
70. Poteser M, Romanin C, Schreibmayer W, Mayer B, Groschner K. S-nitrosation controls gating and conductance of the a1 subunit of class C L-type Ca2+ channels. J Biol Chem 2001;276:14797-14803.
71. Sun J, Picht E, Ginsburg KS, Bers DM, Steenbergen C, Murphy E. Hypercontractile female hearts exhibit increased S-nitrosylation of the L-type Ca2+ channel a1 subunit and reduced ischemia/reperfusion injury. Circ Res 2006;98:403-411.
72. Sun J, Morgan M, Shen RF, Steenbergen C, Murphy E. Preconditioning results in S-nitrosylation of proteins involved in regulation of mitochondrial energetics and calcium transport. Circ Res 2007;101:1155-1163. (Pubitemid 350146442)
73. Gonzalez DR, Beigi F, Treuer AV, Hare JM. Deficient ryanodine receptor S-nitrosylation increases sarcoplasmic reticulum calcium leak and arrhythmogenesis in cardiomyocytes. Proc Natl Acad Sci USA 2007;104:20612-20617.
74. Garofalo F, Parisella ML, Amelio D, Tota B, Imbrogno S. Phospholamban Snitrosylation modulates Starling response in fish heart. Proc Biol Sci 2009;276: 4043-4052.
75. Koenitzer JR, Freeman BA. Redox signaling in inflammation: interactions of endogenous electrophiles and mitochondria in cardiovascular disease. Ann N Y Acad Sci 2010; 1203:45-52.
76. Rudolph V, Rudolph TK, Schopfer FJ, Bonacci G, Woodcock SR, Cole MP et al. Endogenous generation and protective effects of nitro-fatty acids in a murine model of focal cardiac ischaemia and reperfusion. Cardiovasc Res 2010;85:155-166.
77. Pokreisz P, Vandenwijngaert S, Bito V, Van den Bergh A, Lenaerts I, Busch C et al. Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice. Circulation 2009;119:408-416.
78. Vandeput F, Krall J, Ockaili R, Salloum FN, Florio V, Corbin JD et al. cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium. J Pharmacol Exp Ther 2009;330:884-891.
79. Korkmaz S, Radovits T, Barnucz E, Hirschberg K, Neugebauer P, Loganathan S et al. Pharmacological activation of soluble guanylate cyclase protects the heart against ischemic injury. Circulation 2009;120:677-686.
80. Krieg T, Liu Y, Rutz T, Methner C, Yang XM, Dost T et al. BAY 58-2667, a nitric oxide-independent guanylyl cyclase activator, pharmacologically post-conditions rabbit and rat hearts. Eur Heart J 2009;30:1607-1613.
81. Lapp H, Mitrovic V, Franz N, Heuer H, Buerke M, Wolfertz J et al. Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure. Circulation 2009;119:2781-2788.
82. Geschka S, Kretschmer A, Sharkovska Y, Evgenov OV, Lawrenz B, Hucke A et al. Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats. PLoS One 2011;6:e21853.
83. Gori T, Burstein JM, Ahmed S, Miner SE, Al-Hesayen A, Kelly S et al. Folic acid prevents nitroglycerin-induced nitric oxide synthase dysfunction and nitrate tolerance: a human in vivo study. Circulation 2001;104:1119-1123. (Pubitemid 32830394)
84. Moens AL, Claeys MJ, Wuyts FL, Goovaerts I, Van Hertbruggen E, Wendelen LC et al. Effect of folic acid on endothelial function following acute myocardial infarction. Am J Cardiol 2007;99:476-481. (Pubitemid 46215548)
85. Moens AL, Champion HC, Claeys MJ, Tavazzi B, Kaminski PM, Wolin MS et al. Highdose folic acid pretreatment blunts cardiac dysfunction during ischemia coupled to maintenance of high-energy phosphates and reduces postreperfusion injury. Circulation 2008;117:1810-1819. (Pubitemid 351507469)
86. Gauthier C, Leblais V, Kobzik L, Trochu JN, Khandoudi N, Bril A et al. The negative inotropic effect of b3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle. J Clin Invest 1998;102:1377-1384. (Pubitemid 28467566)
87. Varghese P, Harrison RW, Lofthouse RA, Georgakopoulos D, Berkowitz DE, Hare JM. b3-Adrenoceptor deficiency blocks nitric oxide-dependent inhibition of myocardial contractility. J Clin Invest 2000;106:697-703.
88. Dessy C, Balligand JL. Beta3-adrenergic receptors in cardiac and vascular tissues: emerging concepts and therapeutic perspectives. Adv Pharmacol 2010;59:135-163.
89. Gauthier C, Rozec B, Manoury B, Balligand JL. Beta-3 adrenoceptors as new therapeutic targets for cardiovascular pathologies. Curr Heart Fail Rep 2011;8:184-192.
90. Moniotte S, Kobzik L, Feron O, Trochu JN, Gauthier C, Balligand JL. Upregulation of b3-adrenoceptors and altered contractile response to inotropic amines in human failing myocardium. Circulation 2001;103:1649-1655. (Pubitemid 32246612)
91. Hammond J, Balligand JL. Human beta-3 adrenoreceptor over-expression inhibits neurohormones-induced cardiac hypertrophy in vitro and in vivo. Cardiovasc Res 2010;87:S91.
92. Kohout TA, Takaoka H, McDonald PH, Perry SJ, Mao L, Lefkowitz RJ et al. Augmentation of cardiac contractility mediated by the human b3-adrenergic receptor overexpressed in the hearts of transgenic mice. Circulation 2001;104:2485-2491. (Pubitemid 33108385)
93. Moens AL, Leyton-Mange JS, Niu X, Yang R, Cingolani O, Arkenbout EK et al. Adverse ventricular remodeling and exacerbated NOS uncoupling from pressure-overload in mice lacking the b3-adrenoreceptor. J Mol Cell Cardiol 2009; 47:576-585.
94. Calvert JW, Condit ME, Aragon JP, Nicholson CK, Moody BF, Hood RL et al. Exercise protects against myocardial ischemia-reperfusion injury via stimulation of b3-adrenergic receptors and increased nitric oxide signaling: role of nitrite and nitrosothiols. Circ Res 2011;108:1448-1458.
95. Bundgaard H, Liu CC, Garcia A, Hamilton EJ, Huang Y, Chia KK et al. b3 adrenergic stimulation of the cardiac Na+-K+ pump by reversal of an inhibitory oxidative modification. Circulation 2010;122:2699-2708.
96. Flather MD, Shibata MC, Coats AJ, van Veldhuisen DJ, Parkhomenko A, Borbola J et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215-225. (Pubitemid 40222359)
97. Dessy C, Saliez J, Ghisdal P, Daneau G, Lobysheva II, Frerart F et al. Endothelial b3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation b-blocker nebivolol. Circulation 2005;112:1198-1205. (Pubitemid 41216127)
98. Rozec B, Erfanian M, Laurent K, Trochu JN, Gauthier C. Nebivolol, a vasodilating selective b1-blocker, is a b3-adrenoceptor agonist in the nonfailing transplanted human heart. J Am Coll Cardiol 2009;53:1532-1538.
99. Sorrentino SA, Doerries C, Manes C, Speer T, Dessy C, Lobysheva I et al. Nebivolol exerts beneficial effects on endothelial function, early endothelial progenitor cells, myocardial neovascularization, and left ventricular dysfunction early after myocardial infarction beyond conventional b1-blockade. J Am Coll Cardiol 2011;57:601-611.
100. Balligand JL, Kelly RA, Marsden PA, Smith TW, Michel T. Control of cardiac muscle cell function by an endogenous nitric oxide signaling system. Proc Natl Acad Sci USA 1993;90:347-351. (Pubitemid 23010307)
101. Balligand JL, Ungureanu D, Kelly RA, Kobzik L, Pimental D, Michel T et al. Abnormal contractile function due to induction of nitric oxide synthesis in rat cardiac myocytes follows exposure to activated macrophage-conditioned medium. J Clin Invest 1993; 91:2314-2319. (Pubitemid 23141511)
102. Sears CE, Bryant SM, Ashley EA, Lygate CA, Rakovic S,Wallis HL et al. Cardiac neuronal nitric oxide synthase isoform regulates myocardial contraction and calcium handling. Circ Res 2003;92:e52-e59.
103. Barouch LA, Harrison RW, Skaf MW, Rosas GO, Cappola TP, Kobeissi ZA et al. Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms. Nature 2002;416:337-339.
104. Barouch LA, Cappola TP, Harrison RW, Crone JK, Rodriguez ER, Burnett AL et al. Combined loss of neuronal and endothelial nitric oxide synthase causes premature mortality and age-related hypertrophic cardiac remodeling in mice. J Mol Cell Cardiol 2003;35:637-644. (Pubitemid 36677447)
105. Liu YH, Carretero OA, Cingolani OH, Liao TD, Sun Y, Xu J et al. Role of inducible nitric oxide synthase in cardiac function and remodeling in mice with heart failure due to myocardial infarction. Am J Physiol Heart Circ Physiol 2005;289:H2616-H2623. (Pubitemid 41698578)
106. Bolli R, Manchikalapudi S, Tang XL, Takano H, Qiu Y, Guo Y et al. The protective effect of late preconditioning against myocardial stunning in conscious rabbits is mediated by nitric oxide synthase. Evidence that nitric oxide acts both as a trigger and as a mediator of the late phase of ischemic preconditioning. Circ Res 1997;81: 1094-1107. (Pubitemid 27514960)
107. Das A, Xi L, Kukreja RC. Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling. J Biol Chem 2005;280:12944-12955.
108. Marfella R, Di Filippo C, Esposito K, Nappo F, Piegari E, Cuzzocrea S et al. Absence of inducible nitric oxide synthase reduces myocardial damage during ischemia reperfusion in streptozotocin-induced hyperglycemic mice. Diabetes 2004;53:454-462. (Pubitemid 38174563)
109. Kobayashi N, Horinaka S, Mita S, Yoshida K, Honda T, Kobayashi T et al. Aminoguanidine inhibits mitogen-activated protein kinase and improves cardiac performance and cardiovascular remodeling in ailing hearts of salt-sensitive hypertensive rats. J Hypertens 2002;20:2475-2485. (Pubitemid 36026861)
110. Jones SP, Greer JJ, Kakkar AK, Ware PD, Turnage RH, Hicks M et al. Endothelial nitric oxide synthase overexpression attenuates myocardial reperfusion injury. Am J Physiol Heart Circ Physiol 2004;286:H276-H282. (Pubitemid 38049490)
111. Brunner F, Maier R, Andrew P,Wolkart G, Zechner R, Mayer B. Attenuation of myocardial ischemia/reperfusion injury in mice with myocyte-specific overexpression of endothelial nitric oxide synthase. Cardiovasc Res 2003;57:55-62. (Pubitemid 36009436)
112. Szelid Z, Pokreisz P, Liu X, Vermeersch P, Marsboom G, Gillijns H et al. Cardioselective nitric oxide synthase 3 gene transfer protects against myocardial reperfusion injury. Basic Res Cardiol 2010;105:169-179.
113. Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 2005;11:214-222. (Pubitemid 40321358)
114. Takimoto E, Champion HC, Li M, Ren S, Rodriguez ER, Tavazzi B et al. Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. J Clin Invest 2005;115:1221-1231. (Pubitemid 40629040)